This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pyle Disease (Metaphyseal Dysplasia)필레병 (Pyle병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q78.5 (metaphyseal dysplasia) | Special Copayment Reduction: V215
B. SynonymsMetaphyseal Dysplasia, Pyle's disease, Pyle syndrome
C. Adult onsetLikelihood of first onset in adulthood low to moderate — skeletal abnormalities are present congenitally, but in mild cases they may be discovered incidentally on radiographs in childhood or adolescence, or symptoms such as knock-knee (genu valgum) and scoliosis may first attract clinical attention after reaching adulthood.
1. HistoryMetaphyseal dysplasia first described by Edwin Pyle in 1931. Established as an independent disease distinct from craniometaphyseal dysplasia.
2. CausesLoss of Wnt signaling pathway inhibition due to SFRP3 (FRZB) gene variants. Autosomal recessive (AR) inheritance.
3. GeneticsFRZB gene (2q32.1), autosomal recessive. Deficiency of the Wnt antagonist SFRP3 protein → metaphyseal Wnt overactivity → impaired cortical bone formation.
4. General epidemiologyVery rare disease. About 100 cases reported worldwide. Equal frequency in males and females. Relatively high incidence in populations with frequent consanguineous marriage.
5. PathophysiologyWnt/β-catenin signaling overactivity due to SFRP3 deficiency → thinning of metaphyseal cortical bone (Erlenmeyer flask deformity) → increased fragility of long bones.
6. SymptomsGenu valgum, scoliosis, tendency to fracture. Skull and spine are relatively preserved, so neurologic complications are rare.
7. SignsBilateral symmetric metaphyseal widening, Erlenmeyer flask deformity, cortical thinning. No skull or spinal abnormalities — the point of differentiation from craniometaphyseal dysplasia.
8. ScreeningNo specific newborn screening. Skeletal X-rays and genetic testing when there is a family history or an affected sibling. Suspected when limb abnormalities are seen on prenatal ultrasound.
9. DiagnosisWhole-body skeletal X-rays (confirmation of Erlenmeyer flask deformity), molecular genetic testing of the FRZB gene. Differential diagnosis: craniometaphyseal dysplasia, Gaucher disease, thalassemia.
10. TreatmentNo definitive treatment. Orthopedic correction (osteotomy for genu valgum), fracture prevention, physical therapy, surveillance for scoliosis. Multidisciplinary approach centered on symptom relief.
11. PrognosisMostly normal life expectancy. No involvement of the skull or cranial nerves, so neurologic complications are rare. Recurrent fractures and severe genu valgum affect quality of life.
12. PreventionGenetic counseling, preimplantation genetic testing (PGT). Minimizing fracture risk in affected individuals (fall prevention, orthoses). Early detection and treatment of scoliosis.
13. ReferencesPyle E (1931) first description … and 9 other papers and references

1. History

The history of Pyle disease began in 1931 when the American orthopedic surgeon Edwin Pyle reported a skeletal abnormality with unusual metaphyseal widening and cortical thinning of the long bones in two brothers. Pyle named the disease "familial skeletal dystrophism" at the time and described prominent genu valgum, lower limb deformities and generalized metaphyseal thickening and widening in both brothers. Thereafter, the disease came to be called 'Pyle's disease' after its discoverer, or 'metaphyseal dysplasia'.

Initially, Pyle disease and craniometaphyseal dysplasia (CMD) were sometimes considered to lie on a continuum of the same disease. Both are characterized by widening of the long bone metaphyses, but CMD is accompanied by serious neurologic complications such as skull and skull base abnormalities, cranial nerve compression, hearing loss and reduced vision, whereas in Pyle disease the skull and spine are relatively preserved; on this basis Pyle disease was established as a separate, independent disease from the 1960s–70s onward. This clinical differentiation criterion remains the standard in the classification of skeletal dysplasias to this day.

Before the era of molecular genetics, the autosomal recessive inheritance of Pyle disease was confirmed by clinical pedigree studies, but the causative gene was unknown. In 2016, Simsek-Kiper et al. first identified homozygous or compound heterozygous variants of the FRZB (SFRP3) gene in a group of Pyle disease patients, demonstrating at the molecular level that a Wnt signaling pathway antagonist is essential for metaphyseal cortical bone formation. This discovery became an important milestone in understanding the relationship between the Wnt signaling pathway and skeletal development, and subsequent studies also confirmed FRZB variants as the main etiology of Pyle disease. Currently, Pyle disease is listed in OMIM (Online Mendelian Inheritance in Man) as #265900 and is also included in the International Nosology and Classification of Genetic Skeletal Disorders.

In Korea, no independent large-scale epidemiologic study of Pyle disease has yet been reported, but as one of the rare skeletal dysplasias it is included as eligible for Special Copayment Reduction registration (V215), so medical cost support is provided upon diagnosis. Only about 100 cases have been reported in the literature worldwide, so it is classified as an ultra-rare disease. Diagnosis rates are expected to rise in the future with the spread of broad next-generation sequencing (NGS)-based genetic testing.

2. Causes

Pyle disease is an autosomal recessive genetic disease caused by pathogenic variants of the FRZB gene (frizzled-related protein B, also known as SFRP3). The FRZB gene is located on chromosome 2q32.1 and encodes secreted frizzled-related protein 3 (SFRP3), a secreted antagonist of the Wnt signaling pathway. The SFRP3 protein binds Wnt ligands and prevents their binding to Frizzled receptors on the cell membrane, thereby inhibiting Wnt/β-catenin signaling.

The types of FRZB variants are diverse, and variants reported to date include homozygous nonsense variants, missense variants, deletions and splicing variants. Because of autosomal recessive inheritance, one variant allele must be inherited from each parent for the disease to manifest. Heterozygous carriers are generally asymptomatic, and children born to two carriers have a 25% chance of developing the disease. In populations with frequent consanguineous marriage, the frequency of homozygous variants is relatively high and incidence increases.

Whether variants in genes other than FRZB can cause a Pyle disease-like phenotype has not been clearly established to date, but in some cases where FRZB variants are not identified, the possibility of additional genetic heterogeneity has been raised. This is because, given the nature of a rare disease, sufficient gene-phenotype association studies have not been conducted. There is no evidence to date that environmental or acquired factors are involved in causing Pyle disease, and it is regarded as a disease of purely genetic cause.

The reason the Wnt signaling abnormality in Pyle disease is confined to the skeleton is related to the tissue-specific expression pattern of the SFRP3 protein. SFRP3 is highly expressed locally during cartilage and cortical bone formation in the metaphyseal region, and mouse models and human tissue studies have confirmed that Wnt signaling regulation in this region is essential for normal metaphyseal cortical bone formation. FRZB-deficient mice show a phenotype of thinned metaphyseal cortical bone, consistent with the pathologic features of human Pyle disease.

3. Genetics

The FRZB gene that causes Pyle disease is located on the long arm of human chromosome 2 (2q32.1) and consists of a total of 7 exons. The gene product, SFRP3 protein, is a secreted protein of 295 amino acids with a cysteine-rich domain (CRD) at the N-terminus, and this domain plays a key role in binding Wnt ligands. Five members of the SFRP family, SFRP1–5, are known, of which SFRP3 (FRZB) has been confirmed to play the most important role in metaphyseal development.

The mode of inheritance is autosomal recessive (AR). This means that both parents must be carriers of an FRZB variant allele for the disease to manifest in a child. Heterozygous carriers retain 50% of protein function and therefore do not show a skeletal phenotype. Incidence is high in consanguineous families, and parental consanguinity has been confirmed in a considerable number of Pyle disease patients reported to date. For molecular diagnosis, Sanger sequencing or next-generation sequencing (NGS)-based skeletal dysplasia gene panel testing is used.

The pathogenic mechanism of FRZB variants is loss of function (loss-of-function). The variant protein has reduced or lost ability to bind Wnt ligands and fails to exert its inhibitory function on the Wnt/β-catenin signaling pathway. As a result, Wnt signaling is excessively activated in the metaphyseal region, bone remodeling does not proceed normally, and as the cortical bone thins, the characteristic Erlenmeyer flask deformity appears. Cortical bone formation at the endosteum is particularly impaired, so lateral expansion of the metaphyseal region is not corrected and persists.

In genetic counseling for Pyle disease, the autosomal recessive nature of inheritance must be clearly explained to the patient and family. Siblings of an affected patient have a 25% chance of being affected, a 50% chance of being carriers and a 25% chance of being normal. If an affected patient marries a noncarrier, all children are carriers but are not affected. If an affected patient marries a carrier, 50% of the children are affected. In families with molecular confirmation, the birth of an affected fetus can be prevented through preimplantation genetic testing (PGT) or prenatal genetic diagnosis. In Korea, FRZB gene testing is available as part of rare skeletal dysplasia panels, and the disease can be registered as eligible for Special Copayment Reduction V215.

4. General epidemiology

Pyle disease is a very rare skeletal dysplasia worldwide. Only about 100–130 cases had been reported in the literature by 2024, and the exact prevalence is unknown. The incidence is estimated at less than 1 per million, but accurate figures are difficult to determine because of differences in diagnostic criteria and reporting methods. There is no difference in incidence between males and females; consistent with autosomal recessive inheritance, it occurs equally regardless of sex.

In terms of geographic distribution, Pyle disease tends to be reported disproportionately in certain ethnic groups or regions. This is because the frequency of recessive variant carriers is high in populations with founder effects or customs of consanguineous marriage. A characteristic feature is the high proportion of reports from families originating in the Middle East, South Asia and the Mediterranean region, where marriage between cousins is culturally accepted and the frequency of homozygous variants is relatively high. Reported cases from East Asia, including Korea and Japan, are rare, and domestic prevalence data have not yet been published.

Compared with other genetic skeletal dysplasias, the clinical symptoms of Pyle disease are relatively mild, so in inconspicuous cases diagnosis may be delayed or missed. It is presumed that some past cases may have been misclassified because Pyle disease was confused with craniometaphyseal dysplasia (CMD) or other sclerosing bone disorders, so the possibility that the actual incidence is somewhat higher than reported figures cannot be excluded. Diagnosis rates are expected to improve with the widespread use of whole genome sequencing (WGS) and whole exome sequencing (WES) in the future.

In Korea, Pyle disease is designated as eligible for rare disease Special Copayment Reduction (V215), so medical cost support is available upon confirmation. The number of patients in Korea is currently estimated at no more than a few, and the number registered with the Korea Rare Disease Foundation and related academic societies has not been publicly tallied. Strengthening diagnostic capacity at specialized rare skeletal dysplasia clinics (pediatric orthopedics and medical genetics collaboration) is needed, and accumulation of domestic cases and registry studies are recommended.

5. Pathophysiology

The pathophysiology of Pyle disease is overactivation of the Wnt/β-catenin signaling pathway in the metaphyseal region due to SFRP3 (FRZB) protein deficiency. In normal metaphyseal development, the metaphysis near the growth plate cartilage is a region of active bone remodeling, and precise regulation of Wnt signaling in this process is essential for cortical bone formation and medullary cavity formation. In this region, SFRP3 captures Wnt ligands like a scavenger and prevents their binding to the cell membrane receptor Frizzled-LRP5/6 complex, thereby appropriately inhibiting Wnt signaling.

When SFRP3 function is lost because of FRZB variants, Wnt/β-catenin signaling is persistently overactivated in the metaphyseal region. Excessive Wnt signaling promotes osteoblast differentiation, but at the same time regulation of endosteal cortical bone formation breaks down, and the cortical bone becomes abnormally thin. In the normal metaphysis, a process (metaphyseal modeling) occurs in which the wide metaphysis converges to the shape of the narrow diaphysis through bone remodeling with growth, but in Pyle disease this convergence process is defective and the metaphysis remains widened. This is the cause of the characteristic Erlenmeyer flask deformity observed on radiographs.

The Erlenmeyer flask deformity is most prominent in the distal femur and proximal tibia and appears symmetrically in the metaphyses of long bones throughout the body, including the distal humerus, distal radius and ulna, fibula and ribs. Thinning of the cortical bone reduces the mechanical strength of the bone, increasing the risk of fracture with even minor external force, and instability of the metaphyseal structure causes genu valgum and scoliosis. It is understood that skull and spinal abnormalities are mild or absent in Pyle disease because bone remodeling in the skull and spine is relatively less Wnt-dependent than in the metaphyses or other regulatory mechanisms compensate. This is the key pathophysiologic difference from craniometaphyseal dysplasia (CMD).

The effect on bone marrow function is generally mild in Pyle disease. Even if metaphyseal widening encroaches on the medullary cavity, it rarely causes significant impairment of hematopoietic function, which distinguishes it from osteopetrosis, in which the medullary cavity is markedly narrowed. However, there are reports of mild anemia in severe cases, so regular monitoring of bone marrow function is needed. Abnormalities may also occur at muscle attachment sites (entesis), and muscular weakness and fatigue may accompany them.

6. Symptoms

The clinical symptoms of Pyle disease are very diverse, showing a broad phenotypic spectrum ranging from only mild radiologic abnormalities to marked skeletal deformities with functional impairment. In most patients, central nervous system complications involving the skull, cranial nerves or spinal cord do not occur, which is the clinically most important point of differentiation from craniometaphyseal dysplasia (CMD).

The most common symptom is genu valgum (knock-knee), observed in more than half of patients. Because of metaphyseal widening of the distal femur and proximal tibia, the medial structures of the knee weaken, and a deformity in which the lower limbs bend outward progresses during growth. Severe genu valgum causes gait abnormalities, knee pain and joint overload and can lead to early osteoarthritis in adulthood. Scoliosis is also relatively commonly associated, appearing in varying degrees from mild to moderate. As scoliosis progresses, back pain, reduced respiratory function and postural abnormalities result.

An increased tendency to fracture is also an important symptom. Because the cortical bone is thinned, fractures occur more easily than in the general population with even minor trauma, and fractures of long bones such as the femur, tibia and forearm can recur. Some patients develop stress fractures. Muscle pain, fatigue and limb muscle weakness have also been reported, related to the muscular-mechanical imbalance caused by skeletal deformity. Joint hypermobility may be present, explained by ligaments not receiving normal support around the thinned cortical bone.

Skull abnormalities and cranial nerve symptoms generally do not occur in Pyle disease. This is the key point of differentiation from CMD: in CMD, skull thickening, mastoid obliteration, hearing loss due to auditory nerve compression, facial nerve palsy and optic nerve compression commonly occur, whereas such intracranial complications are very rare in Pyle disease. Dental problems (dental anomalies, malocclusion) are also much milder than in CMD or absent. Reduced height or body habitus abnormalities may occur, and in particular final height may be below average in patients with severe lower limb deformities.

7. Signs

The physical and radiologic signs of Pyle disease play a key role in diagnosis. On physical examination, valgus deformity of the lower limbs (genu valgum), gait abnormalities and a sense of bony widening on palpation of the distal femur and proximal tibia are observed. In severe genu valgum, the distance between the two malleoli is markedly increased, and a scissor gait in which the feet strike each other during walking may be seen. When scoliosis is present, lateral curvature of the spine and rib prominence are observed.

Radiologic signs are central to diagnosis. On whole-body skeletal X-ray, the most characteristic finding is the Erlenmeyer flask deformity of the long bone metaphyses. The name refers to a shape in which the metaphysis is broadly widened and the diaphysis relatively narrow, resembling the Erlenmeyer flask used in chemistry laboratories (a flask that tapers from a wide base to a narrow neck). It is most prominent in the distal femur and proximal tibia, and similar findings appear in the distal radius and ulna, distal humerus, ribs and elsewhere.

On X-ray, marked thinning of the metaphyseal cortical bone is observed, with cortical thickness reduced in some cases to half of normal or less. Bone density itself is normal or mildly reduced, and the cortical bone of the diaphysis is relatively close to normal. Unlike in CMD, skull X-rays do not show findings such as skull thickening, mastoid obliteration or excessive ossification of the skull base. Unlike in CMD, spinal X-rays also do not show clear structural abnormalities such as vertebral body deformity or spinal canal stenosis. The difference in these two radiologic findings is the most important criterion for differentiating Pyle disease from CMD.

On bone densitometry (DXA), localized reduction in bone density may be measured because of reduced cortical bone in the metaphyseal region, but this differs from a generalized osteoporosis pattern. Computed tomography (CT) is useful for three-dimensional evaluation of cortical thickness and structural detail and is used in surgical planning. Magnetic resonance imaging (MRI) is used to evaluate bone marrow involvement, cartilage status and nerve compression. A bone scan helps identify fracture sites and areas of activated bone metabolism but shows no specific findings.

8. Screening

There is currently no specific screening test for Pyle disease for the general newborn population. The disease is very rare and is initially clinically asymptomatic or mildly symptomatic, so it is difficult to detect with general screening. However, a systematic screening approach is possible in at-risk families, which helps reduce diagnostic delay and plan the prevention of complications.

Family history-based screening is the most realistic approach. In siblings and children of affected patients (when born to carrier parents), whole-body skeletal X-rays together with molecular genetic testing of the FRZB gene should be performed in infancy or early childhood to achieve early diagnosis. When the molecular variant in the family has been identified, genetic testing can be performed in at-risk infants immediately after birth or within the first few months of life. Because radiologic findings may be mild or nonspecific in infancy, molecular genetic testing is essential for confirmation.

Prenatal diagnosis is possible in families in which an FRZB variant has been identified. The familial variant can be detected directly in fetal DNA obtained by chorionic villus sampling (CVS) at 11–14 weeks of gestation or amniocentesis at 15–20 weeks of gestation. Preimplantation genetic testing (PGT), a method of selecting unaffected embryos during in vitro fertilization, is available at some institutions. When findings suggestive of skeletal dysplasia (abnormal long bone shape, bowing, etc.) are observed on prenatal ultrasound, it is important to link them to further testing.

Situations in which Pyle disease should be suspected clinically are as follows: ① unexplained recurrent fractures in a child, ② bilateral symmetric genu valgum, ③ family history (similar skeletal dysplasia in a sibling or parent), ④ Erlenmeyer flask deformity on radiographs. When suspected, the standard procedure is a whole-body skeletal X-ray (full skeletal survey) together with referral to a medical geneticist or rare skeletal dysplasia specialist. A next-generation sequencing-based skeletal dysplasia gene panel (including FRZB) is an important tool when differential diagnosis is difficult.

9. Diagnosis

Diagnosis of Pyle disease consists of evaluation of clinical symptoms, analysis of radiologic findings and molecular genetic confirmation. The clinical diagnostic criteria consist of ① Erlenmeyer flask deformity of the long bone metaphyses (bilateral, symmetric), ② thinning of the metaphyseal cortical bone, ③ relative preservation of the skull and spine (differentiation from CMD), and ④ an autosomal recessive family history (if present). A clinical diagnosis is possible with typical radiologic findings even without molecular confirmation, but molecular confirmation is essential for genetic counseling and family testing.

Whole-body skeletal X-ray (skeletal survey) is the first and key step in diagnosis. The skull, spine and all limbs are imaged to identify characteristic findings. Erlenmeyer flask deformity of the distal femur and proximal tibia and thinning of the metaphyseal cortical bone appear bilaterally and symmetrically, and the absence of thickening or sclerosis of the skull and spine is characteristic of Pyle disease. Metaphyseal widening is also seen in the ribs, humerus and distal radius and ulna. Compared with the metaphysis, the cortical bone of the diaphysis is relatively close to normal.

Molecular genetic confirmation is achieved by FRZB gene analysis. Direct analysis of FRZB exons by Sanger sequencing or next-generation sequencing (NGS)-based skeletal dysplasia gene panel testing is used. The diagnosis can be confirmed when homozygous or compound heterozygous pathogenic FRZB variants are identified. When the variant is unknown, pathogenic variants can be detected by whole exome sequencing (WES) or whole genome sequencing (WGS). In Korea, rare skeletal dysplasia panel testing (including FRZB) is available at some genetic testing institutions and university hospitals.

Differential diagnosis is very important. The main diseases to be differentiated are: ① craniometaphyseal dysplasia (CMD): distinguished from Pyle disease by skull thickening and symptoms of cranial nerve compression; ② Gaucher disease: shows Erlenmeyer flask deformity from glucocerebroside accumulation in the bone marrow but is accompanied by splenomegaly and hematologic abnormalities; ③ thalassemia: bone marrow hyperplasia and metaphyseal widening due to ineffective erythropoiesis; ④ Camurati-Engelmann disease (progressive diaphyseal dysplasia): diaphyseal cortical thickening is the main finding; ⑤ osteopetrosis: shows generalized osteosclerosis and reduced bone marrow function, and Erlenmeyer flask deformity may also appear. Comprehensive differentiation through clinical symptoms, blood tests (anemia, enzyme abnormalities, etc.), radiologic findings and genetic testing is needed.

10. Treatment

There is currently no curative treatment for Pyle disease. The goals of treatment are prevention and correction of skeletal complications, pain management, maintenance of function and improvement of quality of life. Collaboration of a multidisciplinary team (pediatric orthopedics, medical genetics, rehabilitation medicine, pediatrics, radiology) is essential for optimal treatment outcomes.

Orthopedic treatment is the main treatment method. When genu valgum causes functional impairment or pain, correction of the deformity is attempted during growth through guided growth surgery (e.g., hemiepiphysiodesis), and after growth is complete, proximal tibial osteotomy or distal femoral osteotomy can be performed. Fractures are treated on the same principles as ordinary fractures, but internal fixation may be technically difficult because the cortical bone is thin. For recurrent fractures, intramedullary nailing may be considered.

Treatment of scoliosis is also important. Mild scoliosis (Cobb angle < 25°) is monitored by radiographic follow-up every 6 months to 1 year; in moderate scoliosis (Cobb angle 25–45°), brace treatment is attempted; and in severe scoliosis (Cobb angle > 45°), surgical correction (spinal fusion) is considered. Because progressive scoliosis can affect lung function, pulmonary function tests are also performed regularly.

For drug treatment, nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen are used for pain relief. Bisphosphonate use may be considered for osteoporosis-like bone fragility, but clear efficacy data in Pyle disease are still lacking. Vitamin D and calcium supplementation are recommended to maintain bone health. Experimental agents targeting the Wnt signaling pathway (e.g., anti-sclerostin antibodies) may have therapeutic potential for Pyle disease, but no clinical trials in Pyle disease have been reported to date.

Rehabilitation and physical therapy are important for strengthening muscles, improving joint stability and improving gait. Low-impact aerobic exercise such as swimming and cycling helps maintain musculoskeletal health, while high-impact sports and activities with a high risk of falling are restricted. Orthoses can supplement ankle and knee stability and increase walking efficiency. Education of patients and caregivers (lifestyle habits for fracture prevention, handling emergencies, etc.) is also an important part of treatment.

11. Prognosis

The prognosis of Pyle disease is generally good, and life expectancy is near normal in appropriately managed patients. Unlike craniometaphyseal dysplasia (CMD), there is no serious involvement of the skull and spine, so cranial nerve complications (hearing loss, reduced vision, facial nerve palsy, etc.) do not occur, which works favorably for prognosis. Intellectual ability and language development proceed normally, and there are generally no limitations on academic or occupational ability.

However, complications that affect quality of life can occur. Recurrent fractures are the most common problem; because of cortical thinning, fractures occur easily with even minor trauma, and some patients experience multiple recurrent fractures. Recovery after fracture follows the normal healing process, but when internal fixation is difficult because the cortical bone is thin, the risk of surgical complications may increase. Severe genu valgum can progress to gait impairment, chronic knee pain and early osteoarthritis, which are the main causes of long-term functional impairment.

When scoliosis progresses, back pain and reduced respiratory function can occur, and surgical treatment of severe scoliosis may become necessary. Prognosis after orthopedic surgery is generally good, but technical surgical problems such as reduced screw fixation strength due to cortical thinning can arise. If preventive measures (orthoses, fall prevention education, regular radiographic follow-up) and orthopedic correction are appropriately carried out during growth, functional status in adulthood can be greatly improved.

In long-term follow-up, most Pyle disease patients can live independently and participate in social activities as adults. However, in severe cases, quality of life can be significantly reduced by recurrent fractures, the need for walking aids and repeated orthopedic surgery. If SFRP3 protein supplementation or therapeutics that modulate Wnt signaling are developed in the future, treatment options that fundamentally improve the prognosis of Pyle disease are expected to emerge.

12. Prevention

Primary prevention of Pyle disease (preventing the occurrence of the disease itself) is achieved through genetic counseling and gene-based prevention strategies. When patients with Pyle disease or carrier families plan to have children, genetic counseling from a medical geneticist is essential. When both parents are FRZB variant carriers, the risk that 25% of children will be affected must be clearly communicated, and comprehensive counseling should be provided on the methods, limitations and ethical considerations of preimplantation genetic testing (PGT) and prenatal genetic diagnosis.

Preimplantation genetic testing (PGT) is a method of preventing the birth of an affected child by testing the genes of embryos during in vitro fertilization and implanting only unaffected embryos in the uterus. PGT is possible when the familial FRZB variant has been identified at the molecular level, and it is also available at some reproductive medicine centers in Korea. For prenatal diagnosis, the familial variant can be detected in fetal DNA through chorionic villus sampling (CVS) at 11–14 weeks of gestation or amniocentesis at 15–20 weeks of gestation.

Secondary prevention (prevention of complications) in affected patients is carried out as follows. Environmental modifications for fall prevention (non-slip flooring, bathroom grab bars, use of walking aids, etc.), restriction of high-impact exercise and wearing protective equipment are important for reducing fracture risk. Progression of scoliosis should be detected early with regular radiographic follow-up so that the right time for brace treatment or surgical correction is not missed. Bone health is maintained through vitamin D and calcium supplementation, and risk factors for secondary osteoporosis (smoking, alcohol, long-term steroid use) are managed.

Education of patients and families is also an important component of prevention. How to handle emergency fracture situations, criteria for visiting a medical institution and activity restrictions at home should be clearly taught. Connecting with support groups for patients with rare skeletal dysplasias provides psychosocial support, and sharing experiences with fellow patients helps improve the quality of life of patients and families. Support such as issuing medical certificates is provided so that understanding of Pyle disease at school and work can be increased and appropriate accommodations (exemption from physical education, permission to wear orthoses, etc.) can be made.

13. References

  1. Pyle E. A case of unusual bone development. J Bone Joint Surg Am. 1931;13:874-876.

  2. Simsek-Kiper PO, Utine GE, Alanay Y, et al. Pyle disease caused by a homozygous mutation in the FRZB gene. Hum Genet. 2016;135:1377-1385. DOI: 10.1007/s00439-016-1723-x. PMID: 27730489.

  3. Kornak U, Mundlos S. Genetic disorders of the skeleton: a developmental approach. Am J Hum Genet. 2003;73(3):447-474. DOI: 10.1086/377110. PMID: 12900795.

  4. Spranger JW, Brill PW, Poznanski AK. Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 3rd ed. Oxford University Press; 2012.

  5. Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393-2419. DOI: 10.1002/ajmg.a.61366. PMID: 31633310.

  6. Saber NR, Chan G, Gupta AA, Murnaghan ML. Pyle's metaphyseal dysplasia: a rare cause of pathological fractures. J Pediatr Orthop B. 2012;21(6):561-564. DOI: 10.1097/BPB.0b013e3283568bca. PMID: 22691905.

  7. Logan M, Martin JF, Nagy A, et al. Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis. 2002;33(2):77-80. DOI: 10.1002/gene.10092. PMID: 12112875.

  8. Netter FH. Netter's Orthopaedics. 1st ed. Saunders; 2006. Chapter on metabolic bone disease.

  9. Bhatt S, Bhatt N, Patel P. Pyle disease – a rare case of metaphyseal dysplasia. Indian J Radiol Imaging. 2010;20(1):68-70. DOI: 10.4103/0971-3026.59757. PMID: 20352008.

  10. Krakow D. Skeletal dysplasias. Clin Perinatol. 2015;42(2):301-319. DOI: 10.1016/j.clp.2015.03.003. PMID: 26042907.